مباشر
FierceBiotechWhen Spray Drying Falls Short: A Faster Path ForwardFierceBiotechNovo readies SCD drug from $1.1B Forma buyout for approval push after phase 3 winFierceBiotechRoche boosts diagnostics offerings with $595M Saga buyoutFierceBiotechLilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7BFierceBiotechBiogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibodyModernaWhat's Pushing Moderna Stock Higher Today? - BenzingaNovo NordiskNovo Nordisk to seek oral sickle cell therapy approval after Phase III victory - YahooAbbottDiane Abbott criticises Keir Starmer over Peter Mandelson vetting process - Sky NewsIntuitive SurgicalIntuitive Surgical Q1 2026 Earnings Preview (ISRG:NASDAQ) - Seeking AlphaThermo FisherThermo Fisher: Great Business Still Trading At A Risky Price Before Earnings (NYSE:TMO) - Seeking AlphaThermo FisherHere's How Much $100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today - BenzingaBioWorldBiggest gainers and losers for April 13-17, 2026
Endpoints News ١٨ مارس ٢٠٢٦

Sanofi, AbbVie, Novartis and AstraZeneca face revived 340B pricing case

Sanofi, AbbVie, Novartis and AstraZeneca face revived 340B pricing case

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.